{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dried&page=47",
    "query": {
      "intervention": "Dried",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 1714,
    "total_pages": 172,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dried&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dried&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T15:02:52.992Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03417505",
      "title": "Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye",
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "Scleral lenses treated with Tangible Hydra-PEG",
          "type": "DEVICE"
        },
        {
          "name": "Untreated scleral lenses",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Tangible Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-01-30",
      "completion_date": "2019-01-04",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417505"
    },
    {
      "nct_id": "NCT01315951",
      "title": "Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Seborrheic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Petroleum Jelly",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ascension Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2011-03",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "Burton, Michigan",
      "locations": [
        {
          "city": "Burton",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01315951"
    },
    {
      "nct_id": "NCT05990179",
      "title": "Genomic Uniformed-Screening Against Rare Disease In All Newborns",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Early Onset Genetic Conditions With Near Complete Penetrance"
      ],
      "interventions": [
        {
          "name": "Genome sequencing-based newborn screening",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "1 Month",
        "sex": "ALL",
        "summary": "1 Day to 1 Month"
      },
      "enrollment_count": 100000,
      "start_date": "2022-09-06",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05990179"
    },
    {
      "nct_id": "NCT00900731",
      "title": "A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 μg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1598,
      "start_date": "2009-06",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2011-08-19",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900731"
    },
    {
      "nct_id": "NCT04246866",
      "title": "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration",
        "Geographic Atrophy",
        "Macular Degeneration",
        "Retinal Disease",
        "Retinal Degeneration"
      ],
      "interventions": [
        {
          "name": "GEM103",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gemini Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-12-19",
      "completion_date": "2020-10-21",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246866"
    },
    {
      "nct_id": "NCT07226362",
      "title": "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety, and Tolerability"
      ],
      "interventions": [
        {
          "name": "DHE inhalation powder low dose administered via dry powder inhaler (DPI) device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "DHE inhalation powder high dose administered via dry powder inhaler (DPI) device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "DHE injected intravenously (1 mg)",
          "type": "DRUG"
        },
        {
          "name": "DHE 2 mg administered by nasal spray (Migranal®)",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide 10mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Aspeya Switzerland SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2025-06-09",
      "completion_date": "2025-10-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226362"
    },
    {
      "nct_id": "NCT03597542",
      "title": "Examining the Relationship Between Acute Meal Intake and Inflammation in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Eggs and Carbohydrates",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Illinois at Urbana-Champaign",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-08-29",
      "completion_date": "2018-02-02",
      "has_results": false,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "Urbana, Illinois",
      "locations": [
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597542"
    },
    {
      "nct_id": "NCT03372122",
      "title": "Removal of Bacterial Spores in Adults on Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "General Skin Cleansing"
      ],
      "interventions": [
        {
          "name": "Chlorhexidine Gluconate",
          "type": "DRUG"
        },
        {
          "name": "HUBS with Hibiclens",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Caroline Scott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-12-13",
      "completion_date": "2018-03-07",
      "has_results": false,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03372122"
    },
    {
      "nct_id": "NCT07468175",
      "title": "A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperpigmentation",
        "Dark Spots"
      ],
      "interventions": [
        {
          "name": "Cosmetic dark spot corrector serum",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Revision Skincare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 65 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2024-10-21",
      "completion_date": "2025-03-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 1,
      "location_summary": "Richardson, Texas",
      "locations": [
        {
          "city": "Richardson",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07468175"
    },
    {
      "nct_id": "NCT04268069",
      "title": "Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "PL9643 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2020-02-14",
      "completion_date": "2020-10-05",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-10-27T15:02:52.992Z",
      "location_count": 4,
      "location_summary": "Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04268069"
    }
  ]
}